Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.

Background: Traditional inactivated influenza vaccines are the type of vaccines that were most frequently developed for immunization against the highly pathogenic avian H5N1 influenza virus. However, clinical trials with inactivated influenza vaccines for H5N1 indicated that high doses and at least two immunizations are required for an effective immune response (Nicholson et al., 2001; Treanor, Campbell et al.

Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.

Background: The non-structural protein NS1 of the influenza virus counteracts the interferon-mediated immune response of the host. We investigated the safety and immunogenicity of a trivalent formulation containing influenza H1N1, H3N2 and B strains lacking NS1 (delNS1-trivalent).

Methods: Healthy adult study participants who were seronegative for at least one strain present in the vaccine formulation were randomized to receive a single intranasal dose of delNS1-trivalent vaccine at 7.

A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.

BACKGROUND. The nonstructural protein NS1 of influenza virus counteracts the interferon-mediated immune response of the host. By deleting the open reading frame of NS1, we have generated a novel type of influenza vaccine.

Determination of the pI of human rhinovirus serotype 2 by capillary isoelectric focusing.

Capillary isoelectric focusing was applied to determine the pI value of human rhinovirus serotype 2 (HRV 2), a picornavirus of about 8,500,000 Da in size. Using fused silica capillaries dynamically coated with hydroxypropylmethyl cellulose (added at 0.08% to the catholyte), the virus zone failed to reach the steady state position in the pH gradient within times usually employed in focusing experiments, as the electroosmotic flow (EOF) pushed the analyte zone past the detector.